MS4A7 and glioblastoma: Tracing back to the 123 patients’ clinical information, Kaplan–Meier analysis estimates revealed that MS4A7-l mRNA expression was not significantly associated with patients’ overall survival (OS) (Fig. 2K; P = 0.215); high MS4A7-s mRNA expression was a strong indicator of shortened OS (Fig. 2L; P = 0.0499); MS4A7-s/MS4A7-l ratio is inversely correlated with patient OS (Fig. 2M; P = 0.062), indicating that active alternative splicing product MS4A7-s is oncogenic in GBM.